US · IKT · BIOTECHNOLOGY
Inhibikase Therapeutics, Inc. (IKT) intrinsic value and stock valuation
$1.32as of 2026-11-21 · Mkt cap 326.12M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Inhibikase Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values IKT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IKT’s statements →
Inhibikase Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $260K | $120K | $3.1M |
| Operating income | -$-51.97M | -$-28.59M | -$-20.09M | -$-18.13M | -$-14.77M |
| Net income | -$-48.26M | -$-27.52M | -$-19.03M | -$-18.05M | -$-14.79M |
| EPSd | -$-490.9K | -$-396.77K | -$-3.57M | -$-4.3M | -$-4.88M |
| Operating cash flow | -$-27.79M | -$-19.15M | -$-18.09M | -$-17.35M | -$-14.3M |
| Capital expenditure | -$-10K | $0.00 | -$-10K | -$-240K | $0.00 |
| Free cash flow | -$-27.79M | -$-19.15M | -$-18.1M | -$-17.59M | -$-14.3M |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M |
| Total debt | $0.00 | $110K | $620K | $350K | $250K |
| Net debt | -$-139.22M | -$-56.38M | -$-8.54M | -$-6.84M | -$-40.5M |
| Total equity | $172.9M | $94.9M | $11M | $21M | $38.4M |
| Cash and short-term investments | $178.8M | $97.5M | $13.3M | $23.1M | $40.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $260K | $120K | $3.1M |
| Cost of revenue | $0.00 | $30K | $13.6M | $10K | $11.4M |
| Gross profit | $0.00 | -$-30K | -$-13.36M | $120K | -$-8.26M |
| Research and development expenses | $29.8M | $17.2M | $13.6M | $12M | $11.4M |
| Selling, general and administrative expenses | $23.6M | $11.4M | $6.73M | $6.21M | $0.00 |
| Other expenses | -$-1.37M | -$-30K | -$-13.62M | $0.00 | -$-4.85M |
| Operating expenses | $52M | $28.6M | $6.73M | $18.3M | $6.51M |
| Cost and expenses | $52M | $28.6M | $20.4M | $18.3M | $17.9M |
| Interest income | $3.72M | $1.07M | $1.06M | $70K | $20K |
| Interest expense | $0.00 | $0.00 | $0.00 | $70K | $20K |
| Depreciation and amortization | $60K | $30K | $180K | $10K | $14.8M |
| Ebitda | -$-53.29M | -$-27.49M | -$-18.85M | -$-18.05M | $0.00 |
| Operating income | -$-51.97M | -$-28.59M | -$-20.09M | -$-18.13M | -$-14.77M |
| Total other income/expenses, net | $3.72M | $1.07M | $1.06M | $70K | -$-20K |
| Income before tax | -$-48.26M | -$-27.52M | -$-19.03M | -$-18.05M | -$-14.79M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-48.26M | -$-27.52M | -$-19.03M | -$-18.05M | -$-14.79M |
| Weighted average shares outstanding | $98.3M | $69.4M | $5.33M | $4.2M | $3.03M |
| Weighted average diluted shares outstanding | $98.3M | $69.4M | $5.33M | $4.2M | $3.03M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $178.8M | $97.5M | $13.3M | $23.1M | $40.8M |
| Net receivables | $0.00 | $0.00 | $0.00 | $40K | $110K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $180.1M | $98.5M | $14.2M | $24.4M | $42.5M |
| Property, plant and equipment, net | $0.00 | $150K | $300K | $570K | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.1M | $150K | $300K | $570K | $0.00 |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M |
| Accounts payable | $1.16M | $940K | $650K | $1.15M | $1.09M |
| Short-term debt | $0.00 | $110K | $530K | $150K | $250K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $8.3M | $3.73M | $3.44M | $3.7M | $4.05M |
| Long-term debt | $0.00 | $0.00 | $90K | $210K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $0.00 | $90K | $210K | $0.00 |
| Capital lease obligations | $0.00 | $110K | $240K | $350K | $0.00 |
| Total liabilities | $8.3M | $3.73M | $3.53M | $3.9M | $4.05M |
| Common stock | $130K | $70K | $10K | $0.00 | $30K |
| Retained earnings | -$-142.68M | -$-94.42M | -$-66.9M | -$-47.87M | -$-29.82M |
| Accumulated other comprehensive income (loss) | $20K | -$-40K | $0.00 | $100K | $0.00 |
| Total equity | $172.9M | $94.9M | $11M | $21M | $38.4M |
| Total investments | $39.5M | $41.1M | $4.09M | $15.9M | $0.00 |
| Total debt | $0.00 | $110K | $620K | $350K | $250K |
| Net debt | -$-139.22M | -$-56.38M | -$-8.54M | -$-6.84M | -$-40.5M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-48.26M | -$-27.52M | -$-19.03M | -$-18.05M | -$-14.79M |
| Depreciation and amortization | $60K | $30K | $180K | $10K | $0.00 |
| Stock-based compensation | $15.3M | $8.14M | $500K | $460K | $1.53M |
| Change in working capital | $60K | $200K | $230K | $170K | -$-1.76M |
| Accounts receivable | $0.00 | $0.00 | $40K | $70K | -$-110K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $1.3M |
| Accounts payable | $150K | $270K | -$-500K | $60K | -$-630K |
| Net cash provided by operating activities | -$-27.79M | -$-19.15M | -$-18.09M | -$-17.35M | -$-14.3M |
| Investments in property, plant and equipment | -$-450K | $0.00 | -$-10K | -$-240K | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $240K | $0.00 |
| Net cash used for investing activities | $2.05M | -$-37M | $11.7M | -$-16.01M | $0.00 |
| Common stock issued | $108.5M | $103.5M | $8.54M | $40K | $41.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $108.5M | $103.5M | $8.41M | -$-200K | $41.1M |
| Net change in cash | $82.7M | $47.3M | $1.98M | -$-33.56M | $26.8M |
| Cash at end of period | $139.2M | $56.5M | $9.17M | $7.19M | $40.8M |
| Operating cash flow | -$-27.79M | -$-19.15M | -$-18.09M | -$-17.35M | -$-14.3M |
| Capital expenditure | -$-10K | $0.00 | -$-10K | -$-240K | $0.00 |
| Free cash flow | -$-27.79M | -$-19.15M | -$-18.1M | -$-17.59M | -$-14.3M |
Line items
Line items
Line items
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
- CEO
- Mark T. Iwicki
- Employees
- 35
- Beta
- 0.94
Explore
Frequently asked questions
What is the intrinsic value of Inhibikase Therapeutics, Inc. (IKT)?
InvestorsCraft does not currently publish an intrinsic value for IKT. How the IC value is calculated.
Is IKT undervalued?
InvestorsCraft does not publish an undervaluation signal for IKT at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.